secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001104659-23-115027
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune Q2 FY2024 net loss $60M; cash $496.8M; RP1 data and new CFO announced
-------------------------------------------------------------------------------

- Net loss of $60.0M for Q2 ended Sep 30, 2023, compared to $43.1M loss a year ago.
- Cash, equivalents & short-term investments $496.8M as of Sep 30, 2023; funds operations into H2 2025.
- R&D expenses $49.1M (up from $28.8M) driven by clinical and manufacturing costs for lead programs.
- Appointed Emily Hill as CFO; she was previously CFO of PTC Therapeutics.
- Topline CERPASS trial data and initial IGNYTE melanoma snapshot expected in early December 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465923115027/0001104659-23-115027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465923115027/tm2330041d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-115027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer